Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Disease Progression × Lenalidomide × Clear all

Phase

Status

Sponsor Class

NIH 2 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 237 Lymphoma, Large B-Cell, Diffuse 59 Leukemia, Lymphocytic, Chronic, B-Cell 59 Neoplasms, Plasma Cell 44 Lymphoma, Follicular 42 Lymphoma, Mantle-Cell 39 Lymphoma 38 Recurrence 35 Lymphoma, B-Cell, Marginal Zone 31 Leukemia 28 Leukemia, Myeloid, Acute 25 Lymphoma, B-Cell 18 Myelodysplastic Syndromes 16 Waldenstrom Macroglobulinemia 15 Lymphoma, Non-Hodgkin 15 Smoldering Multiple Myeloma 12 Hodgkin Disease 12 Lymphoma, T-Cell, Peripheral 10 Neoplasms 9 Prostatic Neoplasms 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Lymphoma, T-Cell, Cutaneous 8 Immunoglobulin Light-chain Amyloidosis 8 Burkitt Lymphoma 8 Sezary Syndrome 7 Mycosis Fungoides 7 Neoplasm, Residual 6 Lymphoma, T-Cell 6 Lymphoma, Large-Cell, Anaplastic 6 Intraocular Lymphoma 6

Interventions

pembrolizumab 2 fludarabine 2 Radiosurgery 2 Paclitaxel 2 Cyclophosphamide 2 Cisplatin 2 Carboplatin 2 Anthropogenic Effects 2 venetoclax 1 umbralisib 1 ublituximab 1 pazopanib 1 niraparib 1 lutetium Lu 177 dotatate 1 ibrutinib 1 grapiprant 1 fludarabine phosphate 1 famitinib 1 encorafenib 1 copanlisib 1 cemiplimab 1 capivasertib 1 camrelizumab 1 brigatinib 1 binimetinib 1 axicabtagene ciloleucel 1 avasopasem manganese 1 abexinostat 1 Transplantation, Autologous 1 Temozolomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01191060 2019-04-18

IFM/DFCI2009

University Hospital, Toulouse

Phase 3 Completed

Disease Progression, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡